This Bull Market Indicator called NVDA at $116

Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…

All you have to do is follow this link here

TARS Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 8.25%

Insider Buying (Last 12 Months): $18,960.00

Insider Selling (Last 12 Months): $2,039,734.01

Tarsus Pharmaceuticals Insider Trading History Chart

Tarsus Pharmaceuticals Share Price & Price History

^$46.58

▼ -0.31 (-0.66%)

As of 11/20/2024 01:00 AM ET

Days: 30 | 90 | 365

When it comes to NVDA… “acceleration cycles” are the key

From DTI | Ad

Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.

Use this link to see Nvidia Unchained right away!

Tarsus Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/18/2024	Aziz Mottiwala	Insider	Sell	4,766	$30.60	$145,839.60	54,075
3/18/2024	Bobak R. Azamian	CEO	Sell	10,415	$30.60	$318,699.00	26,456
3/18/2024	Bryan Wahl	General Counsel	Sell	4,436	$30.60	$135,741.60	40,951
3/18/2024	Seshadri Neervannan	COO	Sell	4,879	$30.60	$149,297.40	64,767
12/27/2023	Bobak R. Azamian	CEO	Sell	8,000	$20.22	$161,760.00	830,106
12/20/2023	Bobak R. Azamian	CEO	Sell	40,000	$20.27	$810,800.00	838,106
12/20/2023	Jose M Trevejo	Insider	Sell	2,252	$20.00	$45,040.00	2,251
12/15/2023	Andrew D Goldberg	Director	Buy	1,000	$18.96	$18,960.00	3,000
11/30/2023	Bryan Wahl	General Counsel	Sell	8,356	$16.31	$136,286.36	31,966
11/30/2023	Dianne C Whitfield	Insider	Sell	8,355	$16.31	$136,270.05	26,784
10/18/2023	Bobak R. Azamian	CEO	Sell	8,000	$13.24	$105,920.00	886,106
10/5/2023	Jose M Trevejo	Insider	Sell	1,604	$18.00	$28,872.00	4,503
9/20/2023	Bobak R. Azamian	CEO	Sell	8,000	$17.21	$137,680.00	894,106
8/23/2023	Bobak R. Azamian	CEO	Sell	8,000	$17.23	$137,840.00	902,106
8/15/2023	Elizabeth Yeu Lin	Director	Buy	9,506	$16.80	$159,700.80	15,866
7/19/2023	Aziz Mottiwala	Insider	Sell	2,400	$20.05	$48,120.00	45,806
7/19/2023	Bobak R. Azamian	CEO	Sell	103,900	$20.01	$2,079,039.00	910,106
7/12/2023	Bobak R. Azamian	CEO	Sell	9,000	$17.35	$156,150.00	1,014,006
6/21/2023	Bobak R. Azamian	CEO	Sell	8,000	$18.63	$149,040.00	1,023,006
6/14/2023	Bobak R. Azamian	CEO	Sell	9,000	$18.58	$167,220.00	1,031,006
6/8/2023	Aziz Mottiwala	Insider	Sell	100	$20.00	$2,000.00	48,086
6/8/2023	Bobak R. Azamian	CEO	Sell	3,100	$20.01	$62,031.00	1,040,006
6/6/2023	Aziz Mottiwala	Insider	Sell	2,143	$18.61	$39,881.23	50,686
5/17/2023	Bobak R. Azamian	CEO	Sell	8,000	$15.90	$127,200.00	1,043,106
5/10/2023	Bobak R. Azamian	CEO	Sell	9,000	$16.80	$151,200.00	1,051,106
5/1/2023	Bobak R. Azamian	CEO	Sell	5,841	$15.10	$88,199.10	1,060,106
4/28/2023	Bobak R. Azamian	CEO	Sell	4,278	$15.13	$64,726.14	1,065,947
4/21/2023	Bobak R. Azamian	CEO	Sell	2,311	$15.03	$34,734.33	1,070,225
4/20/2023	Leonard M Greenstein	CFO	Sell	5,000	$14.02	$70,100.00	26,785
4/19/2023	Bobak R. Azamian	CEO	Sell	8,000	$13.60	$108,800.00	1,072,536
3/22/2023	Bobak R. Azamian	CEO	Sell	709	$12.64	$8,961.76	9,334
3/22/2023	Bryan Wahl	General Counsel	Sell	357	$12.64	$4,512.48	16,773
3/22/2023	Jose M Trevejo	Insider	Sell	529	$12.64	$6,686.56	6,572
3/22/2023	Leonard M Greenstein	CFO	Sell	332	$12.64	$4,196.48	32,131
3/22/2023	Seshadri Neervannan	COO	Sell	379	$12.64	$4,790.56	55,086
3/20/2023	Bobak R. Azamian	CEO	Sell	741	$12.61	$9,344.01	10,722
3/20/2023	Bryan Wahl	General Counsel	Sell	357	$12.61	$4,501.77	17,480
3/20/2023	Jose M Trevejo	Insider	Sell	530	$12.61	$6,683.30	7,620
3/20/2023	Leonard M Greenstein	CFO	Sell	333	$12.61	$4,199.13	32,789
3/20/2023	Mark J Holdbrook	VP	Sell	198	$12.61	$2,496.78	3,191
3/20/2023	Seshadri Neervannan	COO	Sell	380	$12.61	$4,791.80	55,837
3/17/2023	Bobak R. Azamian	CEO	Sell	795	$13.28	$10,557.60	11,463
3/16/2023	Bryan Wahl	General Counsel	Sell	337	$13.43	$4,525.91	18,176
3/16/2023	Dianne C Whitfield	Insider	Sell	313	$13.43	$4,203.59	12,872
3/16/2023	Leonard M Greenstein	CFO	Sell	5,313	$13.44	$71,406.72	33,438
3/16/2023	Mark J Holdbrook	VP	Sell	187	$13.43	$2,511.41	3,577
3/16/2023	Seshadri Neervannan	COO	Sell	357	$13.43	$4,794.51	56,577
3/15/2023	Bobak R. Azamian	CEO	Sell	8,000	$13.79	$110,320.00	1,080,536
3/8/2023	Bobak R. Azamian	CEO	Sell	4,853	$15.02	$72,892.06	1,089,253
2/8/2023	Bobak R. Azamian	CEO	Sell	9,000	$15.14	$136,260.00	1,102,106
1/23/2023	Bobak R. Azamian	CEO	Sell	4,856	$15.45	$75,025.20	1,111,106
1/20/2023	Bobak R. Azamian	CEO	Sell	240	$15.00	$3,600.00	1,116,373
1/19/2023	Leonard M Greenstein	CFO	Sell	5,000	$14.56	$72,800.00	39,289
1/18/2023	Bobak R. Azamian	CEO	Sell	8,000	$14.56	$116,480.00	1,116,613
1/11/2023	Bobak R. Azamian	CEO	Sell	3,904	$15.11	$58,989.44	1,124,613
1/9/2023	Bobak R. Azamian	CEO	Sell	729	$15.15	$11,044.35	1,129,422
1/6/2023	Bobak R. Azamian	CEO	Sell	411	$15.00	$6,165.00	1,129,740
12/21/2022	Bobak R. Azamian	CEO	Sell	8,000	$14.57	$116,560.00	1,130,151
12/16/2022	Bobak R. Azamian	CEO	Sell	535	$15.01	$8,030.35	1,138,151
12/15/2022	Leonard M Greenstein	CFO	Sell	5,000	$14.64	$73,200.00	44,289
12/14/2022	Bobak R. Azamian	CEO	Sell	6,420	$15.08	$96,813.60	1,138,686
12/2/2022	Dianne C Whitfield	Insider	Sell	1,154	$16.90	$19,502.60	8,723
11/30/2022	Bryan Wahl	General Counsel	Sell	1,183	$16.50	$19,519.50	16,041
11/30/2022	Dianne C Whitfield	Insider	Sell	1,182	$16.50	$19,503.00	11,042
11/15/2022	Aziz Mottiwala	Insider	Sell	6,857	$17.72	$121,506.04	49,729
10/20/2022	Leonard M Greenstein	CFO	Sell	5,000	$15.92	$79,600.00	54,289
10/19/2022	Bobak R. Azamian	CEO	Sell	8,000	$16.92	$135,360.00	1,162,106
10/12/2022	Bobak R. Azamian	CEO	Sell	9,000	$15.91	$143,190.00	1,170,106
9/21/2022	Bobak R. Azamian	CEO	Sell	8,000	$16.31	$130,480.00	1,179,106
9/15/2022	Leonard M Greenstein	CFO	Sell	5,000	$16.03	$80,150.00	59,289
9/14/2022	Bobak R. Azamian	CEO	Sell	9,000	$16.01	$144,090.00	1,187,106
9/14/2022	Elizabeth Yeu Lin	Director	Buy	18,400	$16.12	$296,608.00	12,040
8/18/2022	Leonard M Greenstein	CFO	Sell	5,000	$16.30	$81,500.00	64,289
8/17/2022	Bobak R. Azamian	CEO	Sell	8,000	$16.59	$132,720.00	1,196,106
5/5/2022	D. Michael Ackermann	Director	Buy	100,000	$13.50	$1,350,000.00	100,000
5/4/2022	Vivo Capital Ix, Llc	Major Shareholder	Sell	19,738	$12.67	$250,080.46	2,474,375
5/2/2022	Vivo Capital Ix, Llc	Major Shareholder	Sell	41,800	$15.19	$634,942.00	2,945,531
12/1/2021	D. Michael Ackermann	Director	Sell	5,833	$24.68	$143,958.44

Tesla Execs are Freaking Out

From Angel Publishing | Ad

It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.

Click here to get the details.

SEC Filings (Institutional Ownership Changes) for Tarsus Pharmaceuticals (NASDAQ:TARS)

90.01% of Tarsus Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Tarsus Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/16/2024	Geode Capital Management LLC	835,790	$27.49M	0.0%	+8.1%	2.197%
11/15/2024	Barclays PLC	98,663	$3.25M	0.0%	+345.9%	0.258%
11/15/2024	Wellington Management Group LLP	145,347	$4.78M	0.0%	+14.2%	0.382%
11/15/2024	State Street Corp	899,379	$29.58M	0.0%	-2.8%	2.364%
11/15/2024	Ikarian Capital LLC	1,030,277	$33.89M	4.6%	+28.7%	2.708%
11/14/2024	Verition Fund Management LLC	23,199	$0.76M	0.0%	N/A	0.061%
11/14/2024	Vestal Point Capital LP	230,000	$7.57M	0.6%	N/A	0.605%
11/14/2024	UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	58,835	$1.94M	0.0%	+10.7%	0.155%
11/14/2024	Ally Bridge Group NY LLC	321,898	$10.59M	5.7%	N/A	0.846%
11/14/2024	Healthcare of Ontario Pension Plan Trust Fund	338,400	$11.13M	0.0%	-13.1%	0.890%
11/13/2024	FMR LLC	5,032	$0.17M	0.0%	+236.6%	0.013%
11/13/2024	The Manufacturers Life Insurance Company	32,929	$1.08M	0.0%	-1.1%	0.087%
11/12/2024	Charles Schwab Investment Management Inc.	290,009	$9.54M	0.0%	+10.7%	0.762%
11/9/2024	Intech Investment Management LLC	8,572	$0.28M	0.0%	N/A	0.023%
11/8/2024	Connor Clark & Lunn Investment Management Ltd.	47,060	$1.55M	0.0%	-44.8%	0.124%
11/8/2024	Jennison Associates LLC	2,178,580	$71.65M	0.0%	+47.2%	5.727%
11/6/2024	Mutual of America Capital Management LLC	130,454	$4.29M	0.0%	N/A	0.343%
11/5/2024	GSA Capital Partners LLP	22,493	$0.74M	0.1%	N/A	0.059%
11/4/2024	Lisanti Capital Growth LLC	39,845	$1.31M	0.3%	N/A	0.105%
10/29/2024	Emerald Advisers LLC	146,298	$4.81M	0.2%	N/A	0.385%
10/29/2024	Harbor Capital Advisors Inc.	18,105	$0.60M	0.0%	+57.5%	0.048%
10/29/2024	Emerald Mutual Fund Advisers Trust	109,692	$3.61M	0.2%	N/A	0.288%
10/25/2024	China Universal Asset Management Co. Ltd.	7,317	$0.24M	0.0%	+64.9%	0.019%
10/23/2024	E. Ohman J or Asset Management AB	46,981	$1.55M	0.0%	+20.5%	0.124%
10/23/2024	Assenagon Asset Management S.A.	1,141,247	$37.54M	0.1%	+7.3%	3.021%
10/19/2024	Allspring Global Investments Holdings LLC	210,531	$6.92M	0.0%	+16.3%	0.557%
10/11/2024	Creative Planning	11,002	$0.36M	0.0%	N/A	0.029%
10/10/2024	Essex Investment Management Co. LLC	109,156	$3.59M	0.6%	N/A	0.287%
10/3/2024	SG Americas Securities LLC	7,242	$0.24M	0.0%	+87.5%	0.019%
9/20/2024	Healthcare of Ontario Pension Plan Trust Fund	389,600	$10.59M	0.0%	-56.6%	1.031%
8/16/2024	Frazier Life Sciences Management L.P.	1,587,527	$43.15M	2.0%	-11.2%	4.202%
8/16/2024	Driehaus Capital Management LLC	364,463	$9.91M	0.1%	+126.1%	0.965%
8/15/2024	Scientech Research LLC	10,619	$0.29M	0.1%	N/A	0.028%
8/15/2024	The Manufacturers Life Insurance Company	33,282	$0.91M	0.0%	+10.3%	0.088%
8/15/2024	Millennium Management LLC	348,586	$9.48M	0.0%	+1,259.3%	0.923%
8/15/2024	Dark Forest Capital Management LP	7,429	$0.20M	0.0%	N/A	0.020%
8/15/2024	Deerfield Management Company L.P. Series C	10,034	$0.27M	0.0%	N/A	0.027%
8/15/2024	AQR Capital Management LLC	7,493	$0.20M	0.0%	-26.5%	0.020%
8/15/2024	Alpha DNA Investment Management LLC	15,174	$0.41M	0.2%	+9.1%	0.040%
8/14/2024	Profund Advisors LLC	9,126	$0.25M	0.0%	+26.8%	0.024%
8/13/2024	Ensign Peak Advisors Inc	594,325	$16.15M	0.0%	-18.3%	1.562%
8/13/2024	Sei Investments Co.	21,298	$0.58M	0.0%	-35.1%	0.056%
8/13/2024	Canada Pension Plan Investment Board	4,200	$0.11M	0.0%	N/A	0.011%
8/12/2024	Hsbc Holdings PLC	9,067	$0.24M	0.0%	N/A	0.024%
8/9/2024	Dimensional Fund Advisors LP	406,899	$11.06M	0.0%	-4.2%	1.077%
8/8/2024	Federated Hermes Inc.	26,483	$0.72M	0.0%	+71.2%	0.070%
8/7/2024	Cowen AND Company LLC	2,197,385	$59.73M	1.7%	+3.5%	5.816%
8/6/2024	Quest Partners LLC	2,255	$61K	0.0%	N/A	0.006%
8/3/2024	TD Asset Management Inc	35,388	$0.96M	0.0%	-27.2%	0.094%
8/1/2024	Rhumbline Advisers	49,660	$1.35M	0.0%	+13.9%	0.131%
7/29/2024	Zurcher Kantonalbank Zurich Cantonalbank	6,109	$0.17M	0.0%	+33.4%	0.016%
7/26/2024	Allspring Global Investments Holdings LLC	181,066	$4.92M	0.0%	-5.8%	0.479%
7/26/2024	Bank of New York Mellon Corp	122,634	$3.33M	0.0%	+27.2%	0.325%
7/25/2024	Calamos Advisors LLC	7,404	$0.20M	0.0%	-25.0%	0.020%
7/18/2024	Assenagon Asset Management S.A.	1,063,422	$28.90M	0.1%	N/A	2.815%
7/12/2024	SG Americas Securities LLC	3,863	$0.11M	0.0%	-63.8%	0.010%
5/16/2024	California State Teachers Retirement System	22,281	$0.81M	0.0%	-5.5%	0.059%
5/16/2024	Janus Henderson Group PLC	8,596	$0.31M	0.0%	N/A	0.023%
5/15/2024	Price T Rowe Associates Inc. MD	347,683	$12.64M	0.0%	N/A	0.920%
5/14/2024	EntryPoint Capital LLC	1,302	$47K	0.0%	-61.5%	0.003%
5/14/2024	Healthcare of Ontario Pension Plan Trust Fund	898,000	$32.64M	0.1%	+1,113.5%	2.377%
5/10/2024	Vanguard Group Inc.	1,826,632	$66.40M	0.0%	+14.5%	4.835%
5/9/2024	Lord Abbett & CO. LLC	82,226	$2.99M	0.0%	N/A	0.218%
5/8/2024	Bleakley Financial Group LLC	6,147	$0.22M	0.0%	N/A	0.016%
5/8/2024	ProShare Advisors LLC	7,631	$0.28M	0.0%	N/A	0.020%
5/8/2024	Russell Investments Group Ltd.	30,036	$1.09M	0.0%	+38,907.8%	0.080%
5/8/2024	Thoroughbred Financial Services LLC	20,964	$0.76M	0.1%	N/A	0.055%
5/7/2024	Sei Investments Co.	32,804	$1.19M	0.0%	+128.2%	0.087%
5/7/2024	Swiss National Bank	42,433	$1.54M	0.0%	+1.4%	0.112%
5/7/2024	SG Americas Securities LLC	10,674	$0.39M	0.0%	-80.6%	0.028%
5/6/2024	Quantbot Technologies LP	11,266	$0.41M	0.0%	N/A	0.030%
5/3/2024	Callan Capital LLC	14,000	$0.51M	0.0%	-17.4%	0.037%
5/2/2024	Jennison Associates LLC	1,330,938	$48.38M	0.0%	N/A	3.523%
5/1/2024	Janney Montgomery Scott LLC	20,901	$0.76M	0.0%	-13.7%	0.055%
4/29/2024	China Universal Asset Management Co. Ltd.	6,567	$0.24M	0.0%	+71.4%	0.017%
4/24/2024	Simplicity Wealth LLC	6,133	$0.22M	0.0%	N/A	0.018%
4/23/2024	Nations Financial Group Inc. IA ADV	6,000	$0.22M	0.0%	N/A	0.018%
4/23/2024	Raymond James Financial Services Advisors Inc.	50,950	$1.85M	0.0%	+16.3%	0.149%
4/22/2024	Vivo Capital LLC	565,550	$20.56M	1.6%	-68.3%	1.653%
4/18/2024	Allspring Global Investments Holdings LLC	192,303	$6.99M	0.0%	+2.6%	0.562%
2/14/2024	TFG Asset Management GP Ltd	800,000	$16.20M	3.9%	+30.1%	2.417%
2/14/2024	RTW Investments LP	3,152,341	$63.84M	1.0%	+9.4%	9.524%
2/13/2024	Tower Research Capital LLC TRC	4,560	$92K	0.0%	+22.1%	0.014%
2/12/2024	Artisan Partners Limited Partnership	390,011	$7.90M	0.0%	-2.3%	1.178%
2/9/2024	Trexquant Investment LP	39,497	$0.80M	0.0%	N/A	0.119%
2/8/2024	Janney Montgomery Scott LLC	24,227	$0.49M	0.0%	+11.5%	0.073%
2/7/2024	Ieq Capital LLC	17,754	$0.36M	0.0%	+63.5%	0.054%
2/7/2024	Vivo Capital LLC	1,784,006	$36.13M	3.0%	-21.1%	5.390%
2/6/2024	Swiss National Bank	41,833	$0.85M	0.0%	-15.4%	0.126%
2/5/2024	Sargent Investment Group LLC	11,117	$0.23M	0.0%	N/A	0.034%
2/2/2024	Callan Capital LLC	16,950	$0.34M	0.0%	+11.5%	0.051%
1/31/2024	abrdn plc	72,032	$1.46M	0.0%	N/A	0.218%
1/25/2024	Allspring Global Investments Holdings LLC	187,414	$3.80M	0.0%	-23.8%	0.566%
1/24/2024	China Universal Asset Management Co. Ltd.	3,832	$78K	0.0%	+362.8%	0.012%
1/16/2024	Raymond James Financial Services Advisors Inc.	43,819	$0.89M	0.0%	+42.9%	0.132%
1/12/2024	SG Americas Securities LLC	54,979	$1.11M	0.0%	+8.4%	0.166%
12/18/2023	Vanguard Group Inc.	1,551,802	$27.58M	0.0%	+25.6%	4.688%
12/6/2023	Citigroup Inc.	4,150	$74K	0.0%	-48.5%	0.013%
11/15/2023	RTW Investments LP	2,880,701	$51.19M	1.1%	+13.1%	8.702%
11/15/2023	Alps Advisors Inc.	24,105	$0.43M	0.0%	+22.4%	0.073%

Data available starting January 2016

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Today's Range

Now: $46.58

$45.73

$47.37

50 Day Range

MA: $38.71

$31.05

$49.42

52 Week Range

Now: $46.58

$15.60

$52.99

Volume

356,373 shs

Average Volume

729,563 shs

Market Capitalization

$1.78 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

Who are the company insiders with the largest holdings of Tarsus Pharmaceuticals?: Tarsus Pharmaceuticals' top insider shareholders include:
Bobak R Azamian (CEO)
Seshadri Neervannan (COO)
Aziz Mottiwala (Insider)
Leonard M Greenstein (CFO)
Bryan Wahl (General Counsel)
Dianne C Whitfield (Insider)
Elizabeth Yeu Lin (Director)
Jose M Trevejo (Insider)
Mark J Holdbrook (VP)
Andrew D Goldberg (Director)
Learn More about top insider investors at Tarsus Pharmaceuticals.
Who are the major institutional investors of Tarsus Pharmaceuticals?: Tarsus Pharmaceuticals' top institutional shareholders include:
Jennison Associates LLC — 5.73%
Assenagon Asset Management S.A. — 3.02%
Ikarian Capital LLC — 2.71%
State Street Corp — 2.36%
Geode Capital Management LLC — 2.20%
Healthcare of Ontario Pension Plan Trust Fund — 0.89%
Learn More about top institutional investors of Tarsus Pharmaceuticals stock.
Which institutional investors are selling Tarsus Pharmaceuticals stock?: Within the last quarter, TARS stock was sold by these institutional investors:
Healthcare of Ontario Pension Plan Trust Fund
Connor Clark & Lunn Investment Management Ltd.
State Street Corp
The Manufacturers Life Insurance Company
In the last year, company insiders that have sold Tarsus Pharmaceuticals company stock include:
Bobak R Azamian (CEO)
Seshadri Neervannan (COO)
Aziz Mottiwala (Insider)
Leonard M Greenstein (CFO)
Bryan Wahl (General Counsel)
Dianne C Whitfield (Insider)
Learn More investors selling Tarsus Pharmaceuticals stock.
Which institutional investors are buying Tarsus Pharmaceuticals stock?: In the previous quarter, TARS stock was acquired by institutional investors including:
Jennison Associates LLC
Ally Bridge Group NY LLC
Ikarian Capital LLC
Vestal Point Capital LP
Emerald Advisers LLC
Mutual of America Capital Management LLC
Emerald Mutual Fund Advisers Trust
Essex Investment Management Co. LLC
Within the last year, these company insiders have bought Tarsus Pharmaceuticals stock:
Bobak R Azamian (CEO)
Seshadri Neervannan (COO)
Learn More investors buying Tarsus Pharmaceuticals stock.